Farmak Tafamidis Meglumine Farmak Tafamidis Meglumine

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find Radio Compass News for Tafamidis Meglumine

    Client Email Product

    Tafamidis Meglumine

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PRICE INFORMATION

    INTERMEDIATES

    DOSSIERs // Finished Dosage Formulations

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS

    DIGITAL CONTENT

    PharmaCompass
    Product SearchProduct Search
    API SUPPLIERS
    API Suppliers

    API Suppliers

    24
    US DMFs Filed

    US DMFs Filed

    11
    CEP/COS Certifications

    CEP/COS Certifications

    0

    JDMFs Filed

    JDMFs Filed

    0

    Other Certificates

    Other Certificates

    4
    Other Suppliers

    Other Suppliers

    20
    API REF. PRICE (USD / KG)
    17,815

    API Market Place

    1
    INTERMEDIATES
    3
    DOSSIERS // FDF
    USA (Orange Book)

    USA (Orange Book)

    1
    Europe

    Europe

    2
    Canada

    Canada

    1
    Australia

    Australia

    0

    South Africa

    South Africa

    0

    Uploaded Dossiers

    Uploaded Dossiers

    1
    GLOBAL SALES (USD Million)

    U.S. Medicaid

    457.00

    Annual Reports

    0

    FDF Market Place

    1
    EXCIPIENTS

    0

    PATENTS & EXCLUSIVITIES

    USFDA Orange Book Patents

    2

    USFDA Exclusivities

    2
    DIGITAL CONTENT

    Blog #PharmaFlow

    1

    News

    16
    REF STANDARD

    EDQM

    0

    USP

    0

    JP

    0

    Other Listed Suppliers

    0

    SERVICES

    0

    Full View ScreenFull Screen View
    HHS asks Supreme Court to reject Pfizer's anti-kickback appeal
    HHS asks Supreme Court to reject Pfizer's anti-kickback appeal

    https://www.fiercepharma.com/pharma/hhs-calls-pfizers-supreme-court-appeal-anti-kickback-statute-far-fetched

    Kevin Dunleavy FIERCEPHARMA
    15 Dec 2022
    Share Share
    Pfizer gains powerful allies in its Vyndaqel copay case
    Pfizer gains powerful allies in its Vyndaqel copay case

    https://www.fiercepharma.com/pharma/pfizer-musters-jj-phrmas-support-closely-watched-vyndaqel-copay-assistance-case

    Fraiser Kansteiner FIERCEPHARMA
    15 Nov 2022
    Share Share
    Pfizer petitions Supreme Court over anti-kickback case
    Pfizer petitions Supreme Court over anti-kickback case

    https://endpts.com/pfizer-petitions-supreme-court-over-anti-kickback-case-says-prior-opinions-could-cut-off-charitable-or-family-aid/

    Zachary Brennan ENDPTS
    18 Oct 2022
    Share Share
    Pfizer’s VYNDAQEL/VYNDAMAX Reduces Risk of All-Cause Mortality by 41% in ATTR-CM
    Pfizer’s VYNDAQEL/VYNDAMAX Reduces Risk of All-Cause Mortality by 41% in ATTR-CM

    https://www.businesswire.com/news/home/20211220005606/en

    BUSINESSWIRE
    20 Dec 2021
    Share Share
    Pfizer’s VYNDAQEL/VYNDAMAX Reduced the Risk of All-Cause Mortality
    Pfizer’s VYNDAQEL/VYNDAMAX Reduced the Risk of All-Cause Mortality

    https://www.biospace.com/article/releases/pfizer-s-vyndaqel-vyndamax-reduced-the-risk-of-all-cause-mortality-by-41-percent-among-patients-with-transthyretin-amyloid-cardiomyopathy-five-year-follow-up-data-demonstrate/

    BIOSPACE
    20 Dec 2021
    Share Share
    Pfizer fails in another challenge to U.S. anti-kickback policies
    Pfizer fails in another challenge to U.S. anti-kickback policies

    https://www.fiercepharma.com/pharma/judge-denies-pfizer-s-request-to-run-2-programs-to-subsidize-patients-for-expensive-heart

    Kevin Dunleavy FIERCEPHARMA
    02 Oct 2021
    Share Share
    Dutch HTA Calls for Big Discount For Pfizer’s Vyndaqel
    Dutch HTA Calls for Big Discount For Pfizer’s Vyndaqel

    https://pink.pharmaintelligence.informa.com/PS144871/Dutch-HTA-Calls-for-Big-Discount-For-Pfizers-Vyndaqel

    Francesca Bruce PINK SHEET
    31 Aug 2021
    Share Share
    Pfizer's new Vyndaqel, Vyndamax reach blockbuster threshold
    Pfizer's new Vyndaqel, Vyndamax reach blockbuster threshold

    https://www.fiercepharma.com/pharma/pfizer-s-vyndaqel-vyndamax-reach-blockbuster-threshold-despite-pandemic-s-challenges

    E. Sagonowsky FIERCE PHARMA
    03 Feb 2021
    Share Share
    Pfizer's Vyndaqel zooms toward blockbusterland, even amid COVID
    Pfizer's Vyndaqel zooms toward blockbusterland, even amid COVID

    https://www.fiercepharma.com/marketing/hey-don-t-forget-vyndaqel-pfizer-rare-heart-disease-drug-s-cruising-fast-toward

    Angus Liu FIERCE PHARMA
    06 Nov 2020
    Share Share
    Pfizer targets anti-kickback rules in Vyndaqel Medicare suit
    Pfizer targets anti-kickback rules in Vyndaqel Medicare suit

    https://www.fiercepharma.com/pharma/pfizer-sues-to-help-vyndaqel-patients-raises-constitutional-question-against-anti-kickback

    Angus Liu FIERCE PHARMA
    30 Jun 2020
    Share Share
    Alnylam scores speedy FDA approval for rare liver disease
    Alnylam scores speedy FDA approval for rare liver disease

    https://www.fiercepharma.com/pharma/alnylam-scores-fda-approval-for-rare-liver-disease-med-givlaari

    K. Blankenship FIERCE PHARMA
    21 Nov 2019
    Share Share
    Pfizer's Vyndaqel franchise, buoyed by diagnose, is poised for 'a decisive beat'
    Pfizer's Vyndaqel franchise, buoyed by diagnose, is poised for 'a decisive beat'

    https://www.fiercepharma.com/marketing/pfizer-s-vyndaqel-franchise-buoyed-by-diagnoses-poised-for-a-decisive-beat-analyst

    A. Liu FIERCE PHARMA
    19 Oct 2019
    Share Share
    After leadership shuffle, Akcea hands heart drug to Pfizer for $250M
    After leadership shuffle, Akcea hands heart drug to Pfizer for $250M

    https://www.fiercebiotech.com/biotech/after-c-suite-shuffle-akcea-hands-heart-drug-to-pfizer-for-250m

    Amirah Al Idrus FIERCE BIOTECH
    08 Oct 2019
    Share Share
    Alnylam's Onpattro back in the game against Ionis, thanks to NICE U-turn
    Alnylam's Onpattro back in the game against Ionis, thanks to NICE U-turn

    https://www.fiercepharma.com/marketing/alnylam-s-onpattro-back-game-ionis-thanks-to-nice-u-turn?utm_source=internal&utm_medium=rss

    Angus Liu FIERCE PHARMA
    09 Jul 2019
    Share Share
    Approved new drug for rare disease
    Approved new drug for rare disease

    https://www.pharmacompass.com/pdf/news/approved-new-drug-for-rare-disease-1478606886.pdf

    ANVISA
    07 Nov 2016
    Share Share
    Pfizer’s Vyndaqel slows neurodegenerative disease, analysis shows
    Pfizer’s Vyndaqel slows neurodegenerative disease, analysis shows

    http://www.pharmatimes.com/news/pfizers_vyndaqel_slows_neurodegenerative_disease,_analysis_shows_1093506

    Selina McKee PHARMATIMES
    10 Aug 2016
    Share Share
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    Inke Tafamidis meglumine

    Access Virtual Booth

    Contact Supplier

    View Presentation

    Nuray Tafamidis Meglumine

    Access Virtual Booth

    Contact Supplier

    View Presentation

    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search